Related Experiment Video
Updated: Apr 15, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Clinical features and disease progression in moyamoya disease patients with Graves disease
Jian-Bin Chen1, Ding Lei1, Min He1
1Department of Neurosurgery, West China Hospital, West China School of Medicine, Sichuan University, Chengdu, People's Republic of China.
Object:
The present study aimed to clarify the incidence and clinical features of disease progression in adult moyamoya disease (MMD) patients with Graves disease (GD) for better management of these patients.
Methods:
During the past 18 years, 320 adult Chinese patients at West China Hospital were diagnosed with MMD, and 29 were also diagnosed with GD. A total of 170 patients (25 with GD; 145 without GD) were included in this study and were followed up. The mean follow-up was 106.4 ± 48.6 months (range 6-216 months). The progression of the occlusive lesions in the major intracranial arteries was measured using cerebral angiography and was evaluated according to Suzuki's angiographic staging. Information about cerebrovascular strokes was obtained from the records of patients' recent clinical visits. Both angiographic progression and strokes were analyzed to estimate the incidences of angiographic progression and strokes using Kaplan-Meier analysis. A multivariate logistic regression model was used to test the effects of sex, age at MMD onset, disease type, strokes, and GD on the onset of MMD progression during follow-up.
Results:
During follow-up, the incidence of disease progression in MMD patients with GD was significantly higher than in patients without GD (40.0% vs 20.7%, respectively; p = 0.036). The interval between initial diagnosis and disease progression was significantly shorter in MMD patients with GD than in patients without GD (p = 0.041). Disease progression occurred in both unilateral MMD and bilateral MMD, but the interval before disease progression in patients with unilateral disease was significantly longer than in patients with bilateral disease (p = 0.021). The incidence of strokes in MMD patients with GD was significantly higher than in patients without GD (48% vs 26.2%, respectively; p = 0.027). The Kaplan-Meier survival curve showed significant differences in the incidence of disease progression (p = 0.038, log-rank test) and strokes (p = 0.031, log-rank test) between MMD patients with GD and those without GD. Multivariate analysis suggested that GD may contribute to disease progression in MMD (OR 5.97, 95% CI 1.24-33.76, p = 0.043).
Conclusions:
The incidence of disease progression in MMD patients with GD was significantly higher than that in MMD patients without GD, and GD may contribute to disease progression in MMD patients. The incidence of strokes was significantly higher in MMD patients with GD than in patients without GD. Management guidelines for MMD patients with GD should be developed.
Insights
Graves disease (GD) significantly increases the risk of moyamoya disease (MMD) progression and strokes in adult patients. Co-occurrence necessitates specialized management guidelines for MMD patients with GD.
Area of Science:
- Neurology
- Endocrinology
- Vascular Medicine
Background:
- Moyamoya disease (MMD) is a rare cerebrovascular disorder characterized by progressive stenosis of intracranial arteries.
- Graves disease (GD) is an autoimmune disorder affecting the thyroid gland, with potential systemic implications.
- The interplay between MMD and GD requires further investigation to optimize patient management.
Purpose of the Study:
- To determine the incidence and clinical features of disease progression in adult MMD patients with co-occurring GD.
- To compare the progression and stroke incidence between MMD patients with and without GD.
- To identify factors influencing disease progression in MMD.
Main Methods:
- Retrospective analysis of 170 adult MMD patients (25 with GD, 145 without GD) over an 18-year period.
- Cerebral angiography used to assess the progression of occlusive lesions based on Suzuki staging.
- Kaplan-Meier analysis for incidence of progression and strokes; multivariate logistic regression for risk factors.
Main Results:
- MMD patients with GD exhibited a significantly higher incidence of disease progression (40.0% vs 20.7%) and strokes (48% vs 26.2%) compared to those without GD.
- The interval to disease progression was shorter in MMD patients with GD.
- Multivariate analysis indicated GD as a potential contributing factor to MMD progression (OR 5.97).
Conclusions:
- Graves disease is associated with a significantly higher risk of moyamoya disease progression and cerebrovascular events.
- Co-occurrence of GD and MMD warrants specific clinical attention and management strategies.
- Development of tailored management guidelines for MMD patients with GD is recommended.
More Related Videos
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Coronary Artery Disease III: Clinical Manifestations
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Myocarditis II: Clinical Features and Diagnostic Tests
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

